SLC5A2 and fatty liver disease: Promisingly, new anti-diabetic drugs like sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1RAs) are being investigated for their potential to reverse liver steatosis and halt the progression of severe fibrosis (80, 94).